Fig. 5: RSK3, the downstream of MYSM1, regulates cellular apoptosis and induces cisplatin resistance.
From: MYSM1 induces apoptosis and sensitizes TNBC cells to cisplatin via RSK3–phospho-BAD pathway
The siRSK3s or negative control siRNA (siCON) were transfected into MYSM1 knockdown MDA-MB-231 and Hs578T cells, and their corresponding negative control cells. The cells were treated with or without cisplatin (5 µg/mL) for 48 h. A Flow cytometry was performed to detect PE/Annexin V staining and evaluate apoptosis. B Flow cytometry was performed to detect DHE staining to evaluate ROS production. C CCK8 assay was performed to measure the cell viability. The MYSM1 knockdown MDA-MB-231 and Hs578T cells and their corresponding negative controls were pretreated with 50 µM of LJH685 or DMSO for 24 h, followed by changing the medium to cisplatin (5 µg/mL) for 48 h. D Flow cytometry was performed to detect PE/Annexin V staining and evaluate apoptosis. E Flow cytometry was performed to detect DHE staining to evaluate ROS production. F CCK8 assay was performed to measure cell viability. All data in the graph bars represent means ± SD. *P < 0.05 and **P < 0.01.
